Latest Articlesddd

During the Departed Week

October 7, 2019 0

The Week in Review #42 During the Departed Week The week started with the market losing …

What Are We Experiencing Now?

October 4, 2019 0

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing …

Seattle Genetics’ Product Tucatinib Beats Agressive Colorectal Cancer. The Stock Price Soars

September 30, 2019 0

Seattle Genetics Stock Rally Seattle Genetics (SGEN) stock has rallied today. It gained around $10; trading …

Enanta Product EPD-305 Has Promising Results for the Treatment NASH

September 28, 2019 0

Enanta Positive Results of EPD-305 for NASH Enanta (ENTA) has positive results from the ARGON-1 Phase …

The Medicines Company: Improving Atherosclerotic Cardiovascular Diseases (ASCVD)

September 26, 2019 0

The Medicines Company ORION-10 Study for ASCVD The Medicines Company (MDCO) announced positive topline results from …

Could Incyte’s Ruxolitinib Cream Effectively Treat Vitiligo?

September 26, 2019 0

Vitiligo Vitiligo is a chronic autoimmune disease. The immune system attacks the pigment-producing melanocyte cells causing …

News from NKTR, BMY and MRK. See Also: Biotechs’ Bizarre Performances in Early Trading Hours Today

September 24, 2019 0

News from Nektar Nektar Therapeutics (NKTR) announced that new data from patients with metastatic triple-negative breast cancer, …

The Value of the Biotech Companies Continued

September 23, 2019 0

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A …

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

September 20, 2019 0

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come …

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

September 17, 2019 0

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics (ATRA) announced the presentation of initial efficacy data as …

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

September 16, 2019 0

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s …

Moderna Therapeutics: A Big Day Filled with Good News

September 13, 2019 0

Moderna Therapeutics Trial Results Moderna Therapeutics (MRNA) trial results mark the first systemic mRNA therapeutic to …

About RegenxBio’s Agreement with Clearside Biomedical and More

September 10, 2019 0

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related …

Amgen’s Oncology Product AMG-510 Meeting An Unmet Need for Kras G12C Mutated Cancers

September 9, 2019 0

Amgen's Outperforming After being boxed in, for the past couple of weeks, Amgen’s (AMGN) stock finally outperformed. …

Vertex: In Pursuit of Cures

September 4, 2019 0

Vertex Pharmaceuticals Is Acquiring Semma Therapeutics Vertex Pharmaceutical (VRTX) entered into a definitive agreement to buy a …

Outperforming Biotechs In a Bad Market Day

September 3, 2019 0

Outperforming Biotechs On August 27, 2019 we posted “The Medicines Company Has Agreeable News” under Today’s …

Gene Therapy and Other Treatments That Work at the Genetic Level

August 30, 2019 0

Gene Therapy Stocks Experiencing Selloffs  Every investor in the biotech sector must have experienced selloffs of …

The Medicines Company Has Agreeable News

August 27, 2019 0

The Medicines Company The Medicines Company (MDCO) focuses on cardiovascular diseases. Major goals are halting the …

Amgen to Acquire Celgene’s Product Otezla at $13.4 Billion

August 26, 2019 0

Amgen Agreement with Celgene for Otezla® In the News Amgen (AMGN) entered into an agreement with …

AstraZeneca and Vertex Both Have Good News

August 21, 2019 0

AstraZeneca: Farxiga for Heart Failure with Reduced Ejection Fraction  AstraZeneca (AZN) has good news. Many of them …